Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: J Geriatr Oncol. 2022 Sep 23;14(1):101377. doi: 10.1016/j.jgo.2022.09.006

Table 1.

Participant Characteristics by Cohort

Characteristic Cohort 1 (triple-negative; n=20) (n, %) Cohort 2 (hormone receptor- positive; n=20) (n, %)
Age (years)
 69–75 11(55) 13(65)
 76–80 7(35) 6(30)
 ≥81 2(10) 1(5)
Median age (range) 74.5(69–83) 73.5(69–86)
Baseline frailty scorea
 Robust (0–0.2) 8(40) 18(90)
 Pre-frail (>0.2–0.35) 6(30) 1(5)
 Frail (>0.35) 4(20) 1(5)
 Not done 2 (10) 0 (0)
Female 20(100) 20(100)
Non-White race 3(15) 3(15)
Hispanic ethnicity 2(10) 1(5)
Born in U.Sb 14(70) 12(60)
Highest educational
attainment 5(25) 3(15)
 High school graduate or less 6(30) 2(10)
 Some college or tech school 7(35) 8(40)
 College or higher 2(10) 7(35)
 Not answered
Income
 Less than $20,000 1(5) 1(5)
 $20,000 to $40,000 4(20) 1(5)
 $40,001 to $60,000 2(10) 3(15)
 $60,001 to $80,000 1(5) 5(25)
 $80,001 or more 5(25) 2(10)
 I prefer not to answer 4(20) 1(5)
 Missing income / did not answer 3 (15) 7 (35)
Married/with domestic partner 6(30) 6(30)
Household composition
 Lives alone 4(20) 5(25)
 Lives with someone 14(70) 8(40)
 Not answered 2(10) 7(35)
With whom do you live?
 Alone 4(20) 5(25)
 Spouse/partner +/− children 6(30) 5(25)
 A child/children 6(30) 1(5)
 A friend 1(5) --
 Other relative 1(5) 2(10)
 Not answered 2(10) 7(35)
Location of residence
 Urban 2(10) 3(15)
 Suburban 14(70) 6(30)
 Rural 2(10) 4(20)
 Not answered 2 (10) 7(35)
Employment
 Employed 3(15) 3(15)
 Retired/not working 15(75) 10(50)
 Not answered 2(10) 7(35)
Stage of diseasec
 I 7(35) 5(25)
 II 9(45) 7(35)
 III 3(15) 7(35)
 Not classified 1(5) 1(5)
Treatment setting
 Neoadjuvant 8(40) 8(40)
 Adjuvant 12(60) 12(60)
a

Rockwood Index47

b

Countries of birth outside the US included Ireland, Mexico, Pakistan, and Portugal. The first language reported across both cohorts was English for all women except for 1 Portuguese, 1 Urdu, and 1 Spanish.

c

Stage is presented as clinical stage if a patient received neoadjuvant therapy and pathological if a patient received adjuvant therapy